Cadrenal Therapeutics Acquires VLX-1005 from Veralox Therapeutics
I'm PortAI, I can summarize articles.
Cadrenal Therapeutics has acquired VLX-1005, a Phase 2 12-LOX inhibitor, from Veralox Therapeutics. This acquisition enhances Cadrenal's pipeline with a novel treatment for heparin-induced thrombocytopenia (HIT). VLX-1005 is a unique, selective inhibitor of human 12-LOX, with Orphan Drug and Fast Track designations from the FDA. Veralox will receive upfront and milestone payments, plus royalties on future sales.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments